Q-omics provides the consensus-scored HIKESHIP1 profile across patient tissues and cancer cell-line models. HIKESHIP1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, HIKESHIP1 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, HIKESHIP1 RNA expression shows 9,144 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight CHOL, and BRCA as cancer lineages where HIKESHIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIKESHIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIKESHIP1 survival associations across molecular data types. HIKESHIP1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIKESHIP1 RNA expression–survival associations across cancer types. High HIKESHIP1 expression shows unfavorable associations in LGG, STAD and HNSC, but favorable associations in CHOL, ESCA and CESC. The CHOL Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for HIKESHIP1 RNA expression.
This table summarizes HIKESHIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HIKESHIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIKESHIP1 shows lower tumor expression in BRCA, KIRC, COAD, STAD, LUSC and LUAD. The BRCA box plot shows higher HIKESHIP1 RNA expression in normal versus tumor tissue (log2 FC = −0.632, t-test p < 0.001).
This table shows molecular features associated with HIKESHIP1 in patient tissues and cancer cell lines. In patient samples, HIKESHIP1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
